Katy Rezvani, MD, PhD, turned her fascination with immunology into a career engineering allogeneic immune cell therapies. On Behind the Breakthroughs, Rezvani explains why NK cells—unlike T cells—hold promise for safer, more accessible cancer treatments, and how her work at MD Anderson is shaping the future of cell therapy.
Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.
Produced by Bill Levine
Hosted by Jonathan D. Grinstein, PhD
Music provided by Artem Hramushkin
Audio mixed and mastered by Jason Mack
Hosted on Acast. See acast.com/privacy for more information.
Behind the Breakthroughs